CoChat
Sign Up
Cited by 109Atrial Fibrillation Management and OutcomesHealth Systems, Economic Evaluations, Quality of LifeAcute Ischemic Stroke Management

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

A Review of the Cost of Atrial Fibrillation

Open access
Wodchis, Walter P., Bhatia, R. Sacha, Leblanc, Kori, Meshkat, Nazanin, Morra, Dante·2012·Value in Health
DOI 10.1016/j.jval.2011.09.009
Open this paper in CoChat — free account

Abstract

Objectives To systematically review and synthesize the literature on the costs of atrial fibrillation (AF) with attention to study design and costing methods, geography, and intervention approaches.Methods A systematic search for previously published studies reporting the costs for AF patients was conducted. Data were analyzed in three steps: first by evaluating overall system costs; second by evaluating the relative contribution of specific cost components; and third by examining variations across study designs, across primary treatment approach, and by geography. Finally, a specific review of the treatment costs associated with anticoagulation treatment was examined given the clinical importance and attention given to these costs in the literature.Results The literature search resulted in 115 articles. On review of the abstracts or full text of these articles, 21 articles met all study criteria and reported on health system AF-related direct costs. A further six articles focused exclusively on anticoagulation costs for patients with AF. The overall average annual system cost across 27 estimates obtained from the literature was $5450 (SD = $3624) in 2010 Canadian dollars and ranged from a low of $1,632 to a high of $21,099. About one-third of these costs could be attributed to anticoagulation management. The largest cost component was acute care, followed by outpatient and physician and then medication-related costs.Conclusion AF-related medical costs are high, reflecting resource-intensive and long-term treatments including anticoagulation treatment. These costs, accompanied with increasing prevalence, justify increased attention to the management of patients with AF. Future studies of AF cost should ensure a broad assessment of the incremental direct medical and societal cost associated with this diagnosis.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jval.2011.09.009

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 56 references

1 of the 56 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Hernandez Madrid, 2005, Transcatheter radiofrequency ablation of the pulmonary veins: cost-benefit ratio and socioeconomic and health care implications [Ablacion transcateter por radiofrecuencia de las venas pulmonares, Investig Cardiovasc, 8, 87
  2. Neeser, 2006, Journal fur Kardiologie, 13, 313

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Wodchis, W. P., Bhatia, R. S., Leblanc, K., Meshkat, N., & Morra, D.
Affiliations
  • University of Toronto (CA)
  • Harvard University (US)
  • University Health Network (CA)
Corresponding author
Wodchis, Walter P.
ORCID
Venue
Value in Health
Publisher
Elsevier BV
Published
2012-03
Volume
15
Issue
2
Pages
240-248
ISSN
1098-3015 (ISSN-L)
DOI
10.1016/j.jval.2011.09.009
OpenAlex
W2029111709
Cited by
109
References
56
Citations by year
2026: 1 · 2025: 3 · 2024: 10 · 2023: 8 · 2022: 13 · 2021: 8 · 2020: 6 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 9 · 2015: 11 · 2014: 6 · 2013: 8 · 2012: 3
FWCI
0.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Value in Health (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
atrial fibrillation, health care costs, direct medical costs, anticoagulation costs, cost components, acute care costs, drug costs, physician costs, economic burden
MeSH terms
Atrial Fibrillation, Costs and Cost Analysis, Humans, Research Design, Health Care Costs, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review